文献速递胸部肿瘤

卡马替尼治疗METex14突变晚期非小细胞肺癌患者的患者报告结局:GEOMETRY mono-1研究结果

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.
PubMed 文献 · Eur J Cancer · 2022-12-10

GEOMETRY mono-1研究报告卡马替尼治疗METex14突变晚期非小细胞肺癌的患者报告结局。初治和经治患者分别接受卡马替尼400mg每日两次,咳嗽早期改善,生活质量至第7周改善并总体维持,支持其应用。

要点

  • 卡马替尼治疗者咳嗽早期即有临床意义的改善,并持续多个周期。
  • 总体健康状况/生活质量至第7周改善,且多数维持。
  • 初治与经治患者总体健康状况/生活质量中位至明确恶化时间分别为16.6个月和12.4个月。

核心结论

  • 卡马替尼与咳嗽的临床意义改善及生活质量保持相关,进一步支持其用于METex14突变晚期非小细胞肺癌患者。

研究设计与样本

  • GEOMETRY mono-1研究(NCT02414139)报告患者报告结局,初治(1L)或经治(2L+)METex14跳跃突变的晚期非小细胞肺癌患者接受卡马替尼400mg每日两次,21天为一周期。
  • 患者报告结局在基线和之后每六周使用EORTC QLQ-C30总体健康状况/生活质量、QLQ-LC13症状和EQ-5D-5L视觉模拟量表问卷采集。

主要发现

  • 截至2020年1月6日,1L组28例中27例、2L+组69例中65例完成了基线患者报告结局,依从率保持>70%。
  • 咳嗽早期改善,整个周期中观察到有意义的改善(较基线≥10分变化),第7周平均变化(标准差):1L组-13.0(39.9),2L+组-8.2(28.4);第43周:1L组-28.2(26.7),2L+组-10.5(27.3)。
  • 以总体健康状况/生活质量和视觉模拟量表评估的生活质量至第7周在1L和2L+患者中改善,改善总体随时间维持。
  • 总体健康状况/生活质量中位至明确恶化时间:1L组16.6个月(95%CI:9.7,不可估计[NE]),2L+组12.4个月(95%CI:4.2,19.4)。
  • 呼吸困难中位至明确恶化时间:1L组19.4个月(95%CI:12.4,NE),2L+组22.1个月(95%CI:9.9,NE);咳嗽和胸痛的中位至明确恶化时间均不可估计。

临床怎么用

  • 作者结论认为卡马替尼与咳嗽的临床意义改善及生活质量保持相关,进一步支持其用于METex14突变晚期非小细胞肺癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Capmatinib, a MET inhibitor, showed substantial antitumour activity with manageable side effects in patients with MET exon 14 (METex14)-mutated advanced non-small cell lung cancer (aNSCLC) in the GEOMETRY mono-1 study. We report patient-reported outcomes (PROs) from this study. METHODS: Enrolled treatment-naïve (1L) or pre-treated (2L+) patients with aNSCLC with a METex14-skipping mutation received 400 mg capmatinib twice daily during 21-day treatment cycles. PROs were collected at baseline and every six weeks thereafter using EORTC QLQ-C30 global health status/quality of life (GHS/QoL), QLQ-LC13 symptoms, and EQ-5D-5L visual analogue scale (VAS) questionnaires. RESULTS: As of 6 January 2020, 27/28 1L and 65/69 2L+ patients had completed PROs at baseline; compliance rates remained >70%. Cough improved early, with meaningful improvements (≥10-point change from baseline) observed throughout cycles (mean change from baseline [SD] by week 7: 1L -13.0 [39.9], 2L+ -8.2 [28.4]; week 43: 1L -28.2 [26.7], 2L+ -10.5 [27.3]). QoL, assessed by GHS/QoL and VAS, improved by week 7 in 1L and 2L+ patients, with improvements generally sustained over time. Median time to definitive deterioration (TTDD) in GHS/QoL was 16.6 months (95% CI: 9.7, not estimable [NE]) in 1L and 12.4 months (95% CI: 4.2, 19.4) in 2L+ patients. Median TTDD for dyspnoea was 19.4 months (95% CI: 12.4, NE) and 22.1 months (95% CI: 9.9, NE) for 1L and 2L+ patients, respectively, and NE for cough and chest pain. CONCLUSIONS: Capmatinib was associated with clinically meaningful improvements in cough and preserved QoL, further supporting its use in patients with METex14-mutated aNSCLC. TRIAL REGISTRATION: ClinicalTrials.gov registry number: NCT02414139.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wolf J, Garon EB, Groen HJM, et al. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study. Eur J Cancer. 2022. PMID: 36822130. doi:10.1016/j.ejca.2022.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。